Cargando…

Return on Investment of the COVID-19 Vaccination Campaign in New York City

IMPORTANCE: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 out...

Descripción completa

Detalles Bibliográficos
Autores principales: Sah, Pratha, Vilches, Thomas N., Moghadas, Seyed M., Pandey, Abhishek, Gondi, Suhas, Schneider, Eric C., Singer, Jesse, Chokshi, Dave A., Galvani, Alison P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679875/
https://www.ncbi.nlm.nih.gov/pubmed/36409495
http://dx.doi.org/10.1001/jamanetworkopen.2022.43127
_version_ 1784834299967569920
author Sah, Pratha
Vilches, Thomas N.
Moghadas, Seyed M.
Pandey, Abhishek
Gondi, Suhas
Schneider, Eric C.
Singer, Jesse
Chokshi, Dave A.
Galvani, Alison P.
author_facet Sah, Pratha
Vilches, Thomas N.
Moghadas, Seyed M.
Pandey, Abhishek
Gondi, Suhas
Schneider, Eric C.
Singer, Jesse
Chokshi, Dave A.
Galvani, Alison P.
author_sort Sah, Pratha
collection PubMed
description IMPORTANCE: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks. OBJECTIVE: To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. EXPOSURES: An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. MAIN OUTCOMES AND MEASURES: Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI. RESULTS: During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. CONCLUSIONS AND RELEVANCE: Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic.
format Online
Article
Text
id pubmed-9679875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-96798752022-12-05 Return on Investment of the COVID-19 Vaccination Campaign in New York City Sah, Pratha Vilches, Thomas N. Moghadas, Seyed M. Pandey, Abhishek Gondi, Suhas Schneider, Eric C. Singer, Jesse Chokshi, Dave A. Galvani, Alison P. JAMA Netw Open Original Investigation IMPORTANCE: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks. OBJECTIVE: To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. EXPOSURES: An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. MAIN OUTCOMES AND MEASURES: Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI. RESULTS: During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. CONCLUSIONS AND RELEVANCE: Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic. American Medical Association 2022-11-21 /pmc/articles/PMC9679875/ /pubmed/36409495 http://dx.doi.org/10.1001/jamanetworkopen.2022.43127 Text en Copyright 2022 Sah P et al. JAMA Network Open. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License.
spellingShingle Original Investigation
Sah, Pratha
Vilches, Thomas N.
Moghadas, Seyed M.
Pandey, Abhishek
Gondi, Suhas
Schneider, Eric C.
Singer, Jesse
Chokshi, Dave A.
Galvani, Alison P.
Return on Investment of the COVID-19 Vaccination Campaign in New York City
title Return on Investment of the COVID-19 Vaccination Campaign in New York City
title_full Return on Investment of the COVID-19 Vaccination Campaign in New York City
title_fullStr Return on Investment of the COVID-19 Vaccination Campaign in New York City
title_full_unstemmed Return on Investment of the COVID-19 Vaccination Campaign in New York City
title_short Return on Investment of the COVID-19 Vaccination Campaign in New York City
title_sort return on investment of the covid-19 vaccination campaign in new york city
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679875/
https://www.ncbi.nlm.nih.gov/pubmed/36409495
http://dx.doi.org/10.1001/jamanetworkopen.2022.43127
work_keys_str_mv AT sahpratha returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT vilchesthomasn returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT moghadasseyedm returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT pandeyabhishek returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT gondisuhas returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT schneiderericc returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT singerjesse returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT chokshidavea returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity
AT galvanialisonp returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity